Video

Eran Orr: Using Virtual Reality to Treat ADHD Patients

Author(s):

The younger generation is able to adapt to new technology for therapy better than previous generations.

With the ongoing coronavirus disease 2019 (COVID-19) pandemic raging on, there is a need for in-home therapy tools for children with attention-deficit hyperactivity disorder (ADHD).

One area where that can be achieved is through virtual reality platforms. While VR likely won’t be able to replace the cancelled sports and social events, it does offer an immersive social experience with a therapeutic arm.

XRHealth recently unveiled a new ADHD virtual reality platform with the goal of improving well-known ADHD cognitive functioning, including attention, impulsivity, and higher and more complex thinking functions such as initiating, organizing, planning, and fully executing daily tasks.

The new system is based on the brain’s ability to restructure itself in attempt to overcome existing challenges, referred to as the brain’s plasticity principle.

Doctors are able to monitor each user for progress biased on sustained focus in the face of distractions.

In an interview with HCPLive®, Evan Orr, Founder and CEO of XRHealth, explained how the virtually reality can be a crucial tool for ADHD patients, particularly during the ongoing pandemic where many are forced home from school, but still unable to go to therapy.

Orr said the use of virtual reality is beneficial because younger ADHD patients are already familiar and comfortable with some of the technology used for the platform.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.